©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. May 27, 2016; 8(5): 363-370
Published online May 27, 2016. doi: 10.4240/wjgs.v8.i5.363
Published online May 27, 2016. doi: 10.4240/wjgs.v8.i5.363
Inflammatory bowel disease surgery in the biologic era
Linda Ferrari, Mukta K Krane, Alessandro Fichera, University of Washington Medical Center, Seattle, WA 98195-6410, United States
Author contributions: All the authors designed the study and wrote the manuscript.
Conflict-of-interest statement: Authors declare no conflict of interest.
Correspondence to: Alessandro Fichera, MD, FACS, FASCRS, University of Washington Medical Center, 1959 NE Pacific Street, Box 356410, Seattle, WA 98195-6410, United States. afichera@uw.edu
Telephone: +1-206-6165709
Received: September 29, 2015
Peer-review started: October 2, 2015
First decision: November 4, 2015
Revised: January 13, 2016
Accepted: March 9, 2016
Article in press: March 14, 2016
Published online: May 27, 2016
Processing time: 231 Days and 7.2 Hours
Peer-review started: October 2, 2015
First decision: November 4, 2015
Revised: January 13, 2016
Accepted: March 9, 2016
Article in press: March 14, 2016
Published online: May 27, 2016
Processing time: 231 Days and 7.2 Hours
Core Tip
Core tip: We review the relationship between biologic agents and surgery in the treatment of inflammatory bowel disease. We also discuss in detail perioperative risks and complications in this setting.